EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 2.0

T cell lymphoproliferative disorders associated with anti-tumor necrosis factor alpha antibody therapy for ulcerative colitis: literature summary

Lindsay A Schmidt, Megan S Lim

Journal of Hematopathology · 2009

DOI: 10.1007/s12308-009-0029-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Hematopathology, 2009. Verfasst von Lindsay A Schmidt und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, M5240 Medical Science I, University of Michigan Medical School, 1301 Catherine Street, Ann Arbor, MI 48109-0602 USA. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 2.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The enhanced risk of development of lymphoproliferative disorders in patients with inflammatory bowel disease has been attributed to immunosuppressive/immunomodulatory therapies. Infliximab is a chimeric monoclonal immunoglobulin G1 antibody directed against tumor necrosis factor alpha (TNF-α) that was approved by the Food and Drug Administration (FDA) in 1998 as an effective therapeutic agent against inflammatory bowel disease. Malignant lymphomas of both B and T cell lineage have been described in patients undergoing therapy involving TNF-α blockade. To date, eight cases of Epstein-Barr virus (EBV)-negative hepatosplenic T cell lymphoma associated with infliximab have been reported to the FDA's Adverse Event Reporting System, as well as several other T cell lymphoproliferative disorders with aggressive clinical outcomes. We present the histologic, immunophenotypic, and molecular features of a T cell lymphoproliferative disorder involving the axillary lymph node of a 33-year-old male following infliximab treatment for ulcerative colitis. These EBV-negative lymphomas suggest that lymphoproliferative disorders following infliximab treatment for inflammatory bowel disease may involve EBV-independent immune dysregulation. The spectrum of lymphoproliferative disorders associated with infliximab and the potential mechanisms by which they occur are discussed.

Autor:innen und Institutionen

  • Department of Pathology, M5240 Medical Science I, University of Michigan Medical School, 1301 Catherine Street, Ann Arbor, MI 48109-0602 USA.

Zitieren

APA

Schmidt, L. A., & Lim, M. S. (2009). T cell lymphoproliferative disorders associated with anti-tumor necrosis factor alpha antibody therapy for ulcerative colitis: literature summary. Journal of Hematopathology. https://doi.org/10.1007/s12308-009-0029-9

Vancouver

Schmidt LA, Lim MS. T cell lymphoproliferative disorders associated with anti-tumor necrosis factor alpha antibody therapy for ulcerative colitis: literature summary. Journal of Hematopathology. 2009. doi:10.1007/s12308-009-0029-9

BibTeX
@article{Schmidt2009,
  author = {Schmidt, Lindsay A and Lim, Megan S},
  title = {T cell lymphoproliferative disorders associated with anti-tumor necrosis factor alpha antibody therapy for ulcerative colitis: literature summary},
  journal = {Journal of Hematopathology},
  year = {2009},
  doi = {10.1007/s12308-009-0029-9}
}
Kostenlos starten →